Paper36765883
In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.
Feijtel D and 10 others. Cancers (Basel), 2023. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. Papers, record 36765883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765883
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2016 | Daniel den Hoed Foundation | PubMed |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27415012 | ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. | Br J Cancer | 2016 | https://conductscience.org/library/papers/27415012 | PubMed |
| 2 | 31015566 | Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs. | Sci Rep | 2019 | https://conductscience.org/library/papers/31015566 | PubMed |
| 3 | 509403 | Transplantation of azaserine-induced carcinomas of pancreas in rats. | Cancer Lett | 1979 | https://conductscience.org/library/papers/509403 | PubMed |
| 4 | 24959847 | Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes. | PLoS One | 2014 | https://conductscience.org/library/papers/24959847 | PubMed |
| 5 | 22202153 | Actinium-225 in targeted alpha-particle therapeutic applications. | Curr Radiopharm | 2011 | https://conductscience.org/library/papers/22202153 | PubMed |
| 6 | 20852858 | Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. | Eur J Nucl Med Mol Imaging | 2011 | https://conductscience.org/library/papers/20852858 | PubMed |
| 7 | 32576907 | Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. | Sci Rep | 2020 | https://conductscience.org/library/papers/32576907 | PubMed |
| 8 | 35294740 | Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. | Endocr Pathol | 2022 | https://conductscience.org/library/papers/35294740 | PubMed |
| 9 | 28076709 | Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28076709 | PubMed |
| 10 | 26596723 | Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. | Eur J Nucl Med Mol Imaging | 2016 | https://conductscience.org/library/papers/26596723 | PubMed |
| 11 | 1662924 | Identification and characterisation in vitro of cells with a non-SCLC cell-like phenotype derived from a continuous SCLC cell line. | Anticancer Res | 1991 | https://conductscience.org/library/papers/1662924 | PubMed |
| 12 | 28331954 | Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. | Eur J Nucl Med Mol Imaging | 2017 | https://conductscience.org/library/papers/28331954 | PubMed |
| 13 | 17051156 | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. | Nature | 2006 | https://conductscience.org/library/papers/17051156 | PubMed |
| 14 | 15285875 | Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948. | Cancer Biother Radiopharm | 2004 | https://conductscience.org/library/papers/15285875 | PubMed |
| 15 | 23103855 | Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. | Cancer Discov | 2013 | https://conductscience.org/library/papers/23103855 | PubMed |
| 16 | 32101125 | Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward. | Curr Top Med Chem | 2020 | https://conductscience.org/library/papers/32101125 | PubMed |
| 17 | 11585290 | [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. | Eur J Nucl Med | 2001 | https://conductscience.org/library/papers/11585290 | PubMed |
| 18 | 29872498 | Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. | Oncotarget | 2018 | https://conductscience.org/library/papers/29872498 | PubMed |
| 19 | 33355125 | The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment. | Sci Adv | 2020 | https://conductscience.org/library/papers/33355125 | PubMed |
| 20 | 21973238 | Slow-cycling therapy-resistant cancer cells. | Stem Cells Dev | 2012 | https://conductscience.org/library/papers/21973238 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42539504 | Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates. | Front Oncol | 2026 | https://conductscience.org/library/papers/42539504 | PubMed |
| 42487019 | Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/42487019 | PubMed |
| 42439911 | Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42439911 | PubMed |
| 42228304 | PARP Inhibitors as Radiosensitizers: Current Evidence and Future Directions. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42228304 | PubMed |
| 41367875 | PARP inhibitors as radiosensitizers: a comprehensive review of preclinical evidence and clinical applications. | Front Oncol | 2025 | https://conductscience.org/library/papers/41367875 | PubMed |
| 40000461 | A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitors. | Eur J Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/40000461 | PubMed |
| 39682120 | Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39682120 | PubMed |
| 39136880 | Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics. | EJNMMI Res | 2024 | https://conductscience.org/library/papers/39136880 | PubMed |
| 39023784 | Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. | Eur J Nucl Med Mol Imaging | 2024 | https://conductscience.org/library/papers/39023784 | PubMed |
| 38948517 | Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38948517 | PubMed |
| 38773983 | Actinium-225 targeted alpha particle therapy for prostate cancer. | Theranostics | 2024 | https://conductscience.org/library/papers/38773983 | PubMed |
| 37351169 | DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo. | Theranostics | 2023 | https://conductscience.org/library/papers/37351169 | PubMed |
| 37190261 | Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37190261 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
| SSTR2 | 6752 | PubTator's text mining | https://conductscience.org/library/genes/6752 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36765883
GET https://conductscience.org/api/papers/v1/36765883/references?page=2